Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics (Premium)
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Kunming Pharmaceutical Corp Announces FY 2013 H1 Net Profit Outlook


Wednesday, 3 Jul 2013 08:00pm EDT 

Kunming Pharmaceutical Corp. announced that it expects its net profit for the first half of fiscal year (FY) 2013 to increase by 35% to 55%, compared to the net profit of the same period in FY 2012 (RMB 79,848,528.98). The Company cited the increased sales of its specialty products as the main reason for the forecast. 

Company Quote

23.86
-0.02 -0.08%
30 Jul 2014